Story excerpt provided by Cincinnati Enquirer.
Written by Anne Saker.
At the beginning of this year, Assurex Health stood in an enviable position for a relatively young biotechnology company.
Its product, a genetic test for people suffering from mental health disorders, was slowly gaining acceptance. The enthusiastic sales force was growing. Venture capital was plentiful.
But top Assurex Health executives including President and Chief Executive Virginia Drosos and its board of directors pondered a fundamental question – how should they manage the company’s future growth. They could keep the company private, issue stock or seek a buyer.
Click here to read the complete article.
Originally published August 5, 2016.